Continue to push ahead with the merger, Pfizer and Mylan make concessions!

Mylan and Pfizer's merger plans have been delayed because of concerns about the COVID-19 pandemicBut in reality, the two companies don't want the expected plan to be extended too muchMarch 31 , the two companies have agreed to meet with intermediary regulators in an effort to move forward with the merger plan to remove obstacles to the European antitrust law , according to the fiercepharma websiteMylan and Pfizer have agreed to back on some of the content of the commission's antitrust review of its outstanding merger, according to a commission filingThe EU has not given specifics about the concessions, but it is usually the most important concern of antitrust lawmakers that are the competitive assets available in the combined portfolio of drugmakers, which would lead to a market monopolyprevious merger between the two companies showed that Mylan has a portfolio of more than 7,500 products, including biosimilars, generics, branded and over-the-counter drugs, with a portfolio of key treatment areas for the central nervous system, anesthesia, infectious diseases and cardiovascular diseaseAt the same time to provide raw materials, and with manufacturing and supply chain advantagesUpjohn has a range of iconic brands of drugs such as Lipto, Ciprosy and Wanaico in the fields of cardiovascular disease, pain, nerves, mental illness, urology, ophthalmology, etc., and has strong commercialization capabilitiesIt can be seen that the products and business capabilities of the two companies are not only complementary, but there are indeed competitive overlapping marketsthe original integration plan was in order and was initially readyIn late February, the two companies also announced the appointment of senior executives in the combined company Viatris, including one current Pfizer board member and eight current directors of Mylan, who will be president of ViatrisHowever, Mylan and Pfizer announced on March 26th that they would delay the merger because of delays in the regulatory review process caused by the COVID-19 pandemicMylan said recently that the merger is expected to be completed in the second half of 2020, the terms of the deal will not changelast week, the Federal Trade Commission and the U.SDepartment of Justice warned that drugmakers could extend the review if they fail to guarantee proper employee work and provide adequate documentation for reviewit is true that the Mylan-Upjohn deal delay is not exceptional in the face of the COVID-19 popularityThe merger of AbbVie and Alcan, which finalized a final deal in June 2019, has also been delayed the two companies announced at the time that the $63 billion merger was expected to be completed in early 2020 In March, the European Commission approved the two companies to spin off gi candidate brazikumab for AstraZeneca Earlier, Eljian also sold two pancreatic replacement enzymes Zenpep and Viokace to Nestle After stripping off three drugs, the way has been paved for final approval At the same time, the two companies have previously reached a "timing agreement" with the FTC, indicating that it is likely that the FTC will make a merger review decision early in the second quarter of 2020, in April but as U.S regulation slows down, rapid approval may take longer than expected In a subsequent statement, AbbVie also postponed the expected merger to May, it turned out In addition to the European Commission and the US FTC, the deal needs to be approved by ireland's High Court because Ofl., based in Ireland Although AbbVie hopes to complete the merger within two months, an FTC spokesman said on March 25 that the FTC is likely to consider postponing the final review indefinitely and possibly delaying the legal deadline for a large merger a spokesman for the FTC noted that the agency's staff was fully operational, but that the commission would not sacrifice the scope and thoroughness of the investigation due to current limitations and timing issues, so the review decision would be delayed The U.S Department of Justice is also considering postponing a review of the AbbVie and ElJian merger and a criminal investigation, bloomberg reported, without giving a reason By introducing drugs such as The Toxin BoTOX, the "heavy bomb" botox, and the fast-growing antipsychotic vraylar, plus AbbVie's own potential heavy-bomb products, the deal is likely to make AbbVie the world's fourth-largest drugmaker, so it's not a good idea to get attention or even filibuster reference source: 1, Mylan, Pfizer offer unprivated concessions as part of eu merger review 2, Pfizer, Mylan say COVID-19 delays will will will theirs Viatris merger